Rich Yang

And so the birth of real-time alerts and alarms and feedback so that you can mitigate severe hypoglycemia and reduce hospital admissions and mortality rates.

And so it's been the single best implementation of a wearable technology to save lives.

And so we've seen the penetration into the insulin using patient population climb.

And it's still not where it needs to be.

But with reimbursement, broad access in the manufacturers at scale right now, it is one of the single, it's probably the best performing medical device in history in terms of

number of users, access, reimbursement.

And so there's a much broader now need for metabolic health literacy outside of people with diabetes using insulin.

But it really evolved around having that continuous feedback in real time.

Glucose is the next vital sign.

It's been really hard to get that information continuously.

And we're the first needle-free approach at doing that.

In vivo sensing is incredibly hard.

For a market this big, you typically would have dozens, if not hundreds of players in market.

And that just goes to show how hard it is to take something that was used for point of care testing and the technology that built billions of units per year in test strips,

It was very difficult to translate into in vivo performance with the appropriate degree of accuracy to mitigate hypoglycemia, to see all the trends in real time.

That continues to be the single greatest barrier to entry for any new technology coming in.

is figuring out the stabilizing chemistry, the manufacturing scale processes for in vivo sensing.

So how do you put a live enzyme on a filament or on the tip of our micro sensors, have it survive sterilization and have it survive dry storage?

And that when you put it on the body, that it actually works right after warmup and be accurate enough for therapeutic decision-making.

So that continues to be a technical feat that very few have been able to accomplish and to be able to get through the FDA.